Fortrea is a global contract research organisation providing Phase I-IV study management, clinical pharmacology and market access solutions to biopharma and MedTech companies in around 100 countries.
Fortrea Holdings Inc. is a global contract research organisation (CRO) that provides Phase I through IV study management, clinical pharmacology and market access solutions to biopharma and MedTech companies. Founded in 2023, the company draws on more than 30 years of heritage from Covance and Labcorp and employs over 14,500 people in operations spanning roughly 100 countries.
Its service portfolio covers end-to-end management of clinical studies from Phase I to Phase IV, including large-scale global trials and focused studies. Alongside this, Fortrea offers clinical pharmacology services and market access solutions, applying science and technology across the clinical development process. The company works with customers in biopharma, MedTech and the wider pharmaceutical sector.
Fortrea describes its working culture around four pillars: Forward Together, Own It, Uphold Integrity and Respect People. Stated commitments include accountability for delivering quality work the first time, putting patient safety first, and an agile approach intended to help bring treatments to patients more quickly. The company partners with customers to understand their needs and states an aim of creating lasting value for stakeholders.
